| Literature DB >> 36080446 |
Xiaoyu Li1,2,3, Xianglei Wang1, Menglu Zhao4, He Zhang5, Chao Liu3.
Abstract
Since the outbreak of the COVID-19 pandemic, traditional Chinese medicine has played an important role in the treatment process. Furthermore, the discovery of artemisinin in Artemisia annua has reduced the incidence of malaria all over the world. Therefore, it is becoming urgent and important to establish a novel method of conducting systematic research on Chinese herbal medicine, improving the medicinal utilization value of traditional Chinese medicine and bringing great benefits to human health all over the world. Fructus Malvae, a kind of Chinese herbal medicine which has been recorded in the "Chinese Pharmacopoeia" (2020 edition), refers to the dry, ripe fruits of Malva verticillata L. Recently, some studies have shown that Fructus Malvae exhibits some special pharmacological activities; for example, it has diuretic, anti-diabetes, antioxidant and anti-tumor properties, and it alleviates hair loss. Furthermore, according to the reports, the active ingredients separated and identified from Fructus Malvae contain some very novel compounds such as nortangeretin-8-O-β-d-glucuronopyranoside and 1-O-(6-deoxy-6-sulfo)-glucopyranosyl-2-O-linolenoyl-3-O-palmitoyl glyceride, which could be screened as important candidate compounds for diabetes- or tumor-treatment drugs, respectively. Therefore, in this research, we take Fructus Malvae as an example and systematically summarize the chemical constituents and pharmacological activity research progress of it. This review will be helpful in promoting the development and application of Fructus Malvae and will also provide an example for other investigations of traditional Chinese medicine.Entities:
Keywords: Chinese herbal medicine; Fructus Malvae; anti-diabetes; anti-tumor; chemical constituents; nortangeretin-8-O-β-d-glucuronopyranoside; pharmacological activity
Mesh:
Substances:
Year: 2022 PMID: 36080446 PMCID: PMC9458057 DOI: 10.3390/molecules27175678
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.927
Figure 1Pictures of Fructus Malvae.
The acid compounds identified from Fructus Malvae.
| No. | Compound Name | Molecular Formula | Medicinal Parts | References |
|---|---|---|---|---|
|
| Caffeic acid | C9H8O4 | The fruit of | [ |
|
| Ferulic acid | C10H10O4 | The fruit of | [ |
|
| Quinic acid | C7H12O6 | The stem, leaf and seed mixture of | [ |
|
| 9,12,13-trihydroxy-octadecadienoic acid | C18H32O5 | The stem, leaf and seed mixture of | [ |
|
| 9,12,13-trihydroxy-octadecenoic acid | C18H34O5 | The stem, leaf and seed mixture of | [ |
|
| Linolenic acid | C18H30O2 | The stem, leaf and seed mixture of | [ |
|
| Oleic acid | C18H34O2 | The seed of | [ |
|
| Myristoleic acid | C14H26O2 | The seed of | [ |
|
| Palmitic acid | C16H32O2 | The seed of | [ |
Fructus Malvae refers to the fruit or seed of Malva verticillata L.
Figure 2The chemical structures of acid compounds identified from Fructus Malvae.
The flavonoids identified from Fructus Malvae.
| No. | Chemical Name | Molecular Formula | Medicinal Parts | Reference |
|---|---|---|---|---|
|
| Myricetin-3-hexoside-glucuronide | C27H28O19 | The stem, leaf and seed mixture of | [ |
|
| Quercetin-3-O-hexoside-glucuronide | C27H28O18 | The stem, leaf and seed mixture of | [ |
|
| Epigallocatechin | C15H14O7 | The stem, leaf and seed mixture of | [ |
|
| Hyperin | C21H20O12 | The stem, leaf and seed mixture of | [ |
|
| Kaempferol-3-O-rutinoside | C27H30O15 | The stem, leaf and seed mixture of | [ |
|
| Kaempferol-3-O-glucoside | C21H20O11 | The stem, leaf and seed mixture of | [ |
|
| Quercitrin | C21H20O11 | The stem, leaf and seed mixture of | [ |
|
| Quercetin-3-O-glucuronide | C21H18O13 | The stem, leaf and seed mixture of | [ |
|
| Catechin | C15H14O6 | The stem, leaf and seed mixture of | [ |
|
| Kaempferol (or luteolin)-3-O-glucuronid | C21H18O12 | The stem, leaf and seed mixture of | [ |
|
| Kaempferide-3-glucuronide | C22H20O12 | The stem, leaf and seed mixture of | [ |
|
| Biochanin A | C16H12O5 | The stem, leaf and seed mixture of | [ |
|
| Rubone | C20H22O7 | The stem, leaf and seed mixture of | [ |
|
| Robinetin trimethyl ether | C18H16O7 | The stem, leaf and seed mixture of | [ |
|
| Rutin | C27H30O16 | The fruit of | [ |
|
| Nortangeretin-8-O-β- | C21H18O13 | The stem, leaf and seed mixture of | [ |
|
| Isoscutellarein 8-O-glucuronopyranoside | C21H18O12 | The stem, leaf and seed mixture of | [ |
|
| Hypolaetin 8-O-glucuronopyranoside | C21H18O13 | The stem, leaf and seed mixture of | [ |
|
| Herbacetin 8-O-glucuronopyranoside | C21H18O13 | The stem, leaf and seed mixture of | [ |
|
| Herbacetin 3-O-glucopyranosyl-8-O-glucuronopyranoside | C27H28O18 | The stem, leaf and seed mixture of | [ |
|
| Isoscutellarein 7-O-glucopyranoside | C21H20O11 | The stem, leaf and seed mixture of | [ |
Fructus Malvae refers to the fruit or seed of Malva verticillata L.
Figure 3The chemical structures of flavonoids identified from Fructus Malvae.
The sterol compounds identified from Fructus Malvae.
| No. | Chemical Name | Molecular Formula | Medicinal Parts | References |
|---|---|---|---|---|
|
| β-sitosterol | C29H50O | The seed of | [ |
|
| Verticilloside | C50H80O22 | The seed of | [ |
|
| Daucosterol | C35H60O6 | The seed of | [ |
Fructus Malvae refers to the fruit or seed of Malva verticillata L.
Figure 4The chemical structures of sterol compounds identified from Fructus Malvae.
The Glycerides identified from Fructus Malvae.
| No. | Chemical Name | Molecular Formula | Medicinal Parts | Reference |
|---|---|---|---|---|
|
| 1-O-palmitoyl glyceride | C19H38O4 | The stem, leaf and seed mixture of | [ |
|
| 1-O-stearoyl glyceride | C21H42O4 | The stem, leaf and seed mixture of | [ |
|
| 1-O-linolenoyl glyceride | C21H36O4 | The stem, leaf and seed mixture of | [ |
|
| 1,2-di-O-linoleoyl glyceride | C39H68O5 | The stem, leaf and seed mixture of | [ |
|
| 1-O-(6-deoxy-6-sulfo)-glucopyranosyl-2-O-linolenoyl-3-O-palmitoyl glyceride | C43H75O12S− | The stem, leaf and seed mixture of | [ |
|
| 1-O-(6-deoxy-6-sulfo)-glucopyranosyl-2,3-di-O-linolenoyl glyceride | C45H73O12S− | The stem, leaf and seed mixture of | [ |
|
| 1-O-galactopyranosyl-3-O-palmitoyl glyceride | C25H48O9 | The stem, leaf and seed mixture of | [ |
|
| 1-O-galactopyranosyl-3-O-stearoyl glyceride | C27H52O9 | The stem, leaf and seed mixture of | [ |
|
| 1-O-galactopyranosyl-3-O-isostearoyl glyceride | C27H52O9 | The stem, leaf and seed mixture of | [ |
|
| 1-O-galactopyranosyl-3-O-linolenoyl glyceride | C27H46O9 | The stem, leaf and seed mixture of | [ |
|
| 1-O-galactopyranosyl-2,3-di-O-palmitoyl glyceride | C41H78O10 | The stem, leaf and seed mixture of | [ |
|
| 1-O-galactopyranosyl-2,3-di-O-linolenoyl glyceride | C45H74O10 | The stem, leaf and seed mixture of | [ |
|
| 1-O-6′-O-(-galactopyranosyl)-galactopyranosyl-3-O-palmitoyl glyceride | C31H58O14 | The stem, leaf and seed mixture of | [ |
|
| O-6′-O-(-galactopyranosyl)-galactopyranosyl-3-O-2-linolenoyl glyceride | C33H56O14 | The stem, leaf and seed mixture of | [ |
|
| 1-O-6′-O-(-galactopyranosyl)-galactopyranosyl-2,3-di-O-palmitoyl glyceride | C47H88O15 | The stem, leaf and seed mixture of | [ |
|
| 1-O-(6-O-galactopyranosyl)-galactopyranosyl-2-O-stearolyl-3-O-linolenoyl glyceride | C51H90O15 | The stem, leaf and seed mixture of | [ |
|
| 1-O-(6-O-galactopyranosyl)-galactopyranosyl-2,3-di-O-linolenoyl glyceride | C51H84O15 | The stem, leaf and seed mixture of | [ |
Fructus Malvae refers to the fruit or seed of Malva verticillata L.
Figure 5The chemical structures of glycerides identified from Fructus Malvae.
The volatile oils identified from Fructus Malvae.
| No. | Chemical Name | Molecular Formula | Medicinal Parts | References |
|---|---|---|---|---|
|
| 1,1-dichloro-2-hexyl-Cyclopropan | C9H16Cl2 | The fruit of | [ |
|
| 3-(Prop-2-enoyloxy)dodecane | C15H28O2 | The fruit of | [ |
|
| 1-(ethenyloxy)-pentane | C7H14O | The fruit of | [ |
|
| 1-methyl-6,7-Dioxabicyclo[3.2.1]octane | C7H12O2 | The fruit of | [ |
|
| 2-methyl-5-(1-methylethenyl)-Cyclohexanol | C10H18O | The fruit of | [ |
|
| trans-1,2-Cyclopentanediol | C5H10O2 | The fruit of | [ |
|
| 3, 5-Octadien-2-ol | C10H18O | The fruit of | [ |
|
| (Z)-2-Octen-2-ol | C8H16O | The fruit of | [ |
|
| Nona-2-en-1-ol | C9H18O | The fruit of | [ |
|
| (E)-2,6-Dimethyl-3,5,7-octatriene-2-ol | C10H16O | The fruit of | [ |
|
| (1S)-1,7,7-trimethyl-Bicyclo[2.2.1] heptan-2-one | C10H16O | The fruit of | [ |
|
| Z,Z-2,5-Pentadecadien-1-ol | C15H28O | The fruit of | [ |
|
| Dihydro-4,4-dimethyl-2(3H)-Furano | C6H10O2 | The fruit of | [ |
|
| Z-1,9-Hexadecadiene | C16H30 | The fruit of | [ |
|
| (E, E)-2,4-Decadiene | C10H18 | The fruit of | [ |
|
| Hexanoic acid | C16H12O2 | The fruit of | [ |
|
| 2-(Prop-2-enoytoxy) tetradecane | C17H32O2 | The fruit of | [ |
|
| 5-hexyldihydro-2(3H)-Furanone | C10H18O2 | The fruit of | [ |
|
| 7-Methyl-Z-tetradecen-1-ol acetate | C17H32O2 | The fruit of | [ |
|
| Dibutylphthalate | C16H22O4 | The fruit of | [ |
|
| 2,5-dihydro-1-nitroso-1H-Pyrrole | C4H6N2O | The fruit of | [ |
|
| 5-(Prop-2-enoyloxy)pentadecane | C18H34O2 | The fruit of | [ |
|
| (E)-2-Octenal | C8H14O | The fruit of | [ |
|
| (Z)-2-Nonenal | C9H16O | The fruit of | [ |
Fructus Malvae refers to the fruit or seed of Malva verticillata L.
Figure 6The chemical structures of volatile oils identified from Fructus Malvae.
The polysaccharides identified from Fructus Malvae.
| No. | Chemical Name | Molecular Formula | Medicinal Parts | References |
|---|---|---|---|---|
|
| MVS-I | -- | The seed of | [ |
|
| MVS-IIA | -- | The seed of | [ |
|
| MVS-IIG | -- | The seed of | [ |
|
| MVS-IIIA | -- | The seed of | [ |
|
| MVS-IVA | -- | The seed of | [ |
|
| MVS-VI | -- | The seed of | [ |
|
| MVS-V | -- | The seed of | [ |
|
| Sucrose | C12H22O11 | The seed of | [ |
|
| Raffinose | C18H32O16 | The seed of | [ |
Fructus Malvae refers to the fruit or seed of Malva verticillata L.
Figure 7The chemical structures of polysaccharides identified from Fructus Malvae.
The amino acids identified from Fructus Malvae.
| No. | Chemical Name | Molecular Formula | Medicinal Parts | References |
|---|---|---|---|---|
|
| C3H7NO2 | The seed of | [ | |
|
| tryptophan | C11H12N2O2 | The stem, leaf and seed mixture of | [ |
|
| Aspartic acid | C4H7NO4 | The fruit of | [ |
|
| Threonine | C4H9NO3 | The fruit of | [ |
|
| Serine | C3H7NO3 | The fruit of | [ |
|
| Glutamic acid | C5H9NO4 | The fruit of | [ |
|
| Proline | C5H9NO2 | The fruit of | [ |
|
| Glycine | C2H5NO2 | The fruit of | [ |
|
| Valine | C5H11NO2 | The fruit of | [ |
|
| l-isoleucine | C6H13NO2 | The fruit of | [ |
|
| Leucine | C6H13NO2 | The fruit of | [ |
|
| Tyrosine | C9H11NO3 | The fruit of | [ |
|
| Phenylalanine | C9H11NO2 | The fruit of | [ |
|
| Histidine | C6H9N3O2 | The fruit of | [ |
|
| Arginine | C6H14N4O2 | The fruit of | [ |
Figure 8The chemical structures of amino acids identified from Fructus Malvae.
The other substances identified from Fructus Malvae.
| No. | Chemical Name | Molecular Formula | Medicinal Parts | Reference |
|---|---|---|---|---|
|
| oleamide | C18H35NO | The seed of | [ |
|
| 1,3-dihydroxyacetone dimer | C6H12O6 | The seed of | [ |
|
| 5-hydroxymethyl furfural | C6H6O3 | The seed of | [ |
|
| 2-hydroxy-gamma-butyrolactone | C4H6O3 | The seed of | [ |
|
| 3,5,6,9-tetrahydroxy-7-megastigmene | C13H24O4 | The stem, leaf and seed mixture of | [ |
Figure 9The chemical structures of other substances identified from Fructus Malvae.
The research progress on the pharmacological activity of Fructus Malvae.
| Pharmacological Activity | Compound/Extract | Experimental Level | Experimental Model | Administration | Dosage/Concentration | Detection Indicator | Effective Dose | Reference |
|---|---|---|---|---|---|---|---|---|
| Diuretic effect | Petroleum ether extract | Whole animal | Water-loaded rat model | Oral administration | 25 mL/kg | Urine volume, urine sodium content, urine potassium content, urine chlorine content (mg) | Effective dose: | [ |
| Ethyl acetate extract | Whole animal | Water-loaded rat model | Oral administration | 25 mL/kg | Urine volume, urine sodium content, urine potassium content, urine chlorine content (mg) | Effective dose: | [ | |
| Anti-diabetic | Ethyl acetate extract | Whole animal | Alloxan-induced islet damage model in zebrafish larvae | Soak absorption | 25~600 μg/mL, | 50% lethal concentration LC50; changes in islet area, changes in fluorescence intensity caused by 2-NBDG | LC50:91.5 μg/mL; | [ |
| n-Butanol extract | Whole animal | Alloxan-induced islet damage model in zebrafish larvae | Soak absorption | 25~600 μg/mL, | 50% lethal concentration LC50; changes in islet area, changes in fluorescence intensity caused by 2-NBDG | LC50:270.9 μg/mL; | [ | |
| Whole animal | Alloxan-induced islet damage model in zebrafish larvae | Soak absorption | 10 μg/mL | Changes in islet area, changes in fluorescence intensity caused by 2-NBDG | Effective dose: | [ | ||
| Water extract | Whole animal | Alloxan-induced islet damage model in zebrafish larvae | Soak absorption | 25~600 μg/mL, | 50% lethal concentration LC50; changes in islet area, changes in fluorescence intensity caused by 2-NBDG | LC50:401.1 μg/mL; | [ | |
| Nortangeretin-8-O-β- | Whole animal | Alloxan-induced islet damage model in zebrafish larvae | Soak absorption | 0.1 μM | Changes in islet area, changes in fluorescence intensity caused by 2-NBDG | Effective dose: | [ | |
| Hypolaetin 8-O-β- | Whole animal | Alloxan-induced islet damage model in zebrafish larvae | Soak absorption | 0.1 μM | Changes in islet area, changes in fluorescence intensity caused by 2-NBDG | Effective dose: | [ | |
| Herbacetin 8-O-β- | Whole animal | Alloxan-induced islet damage model in zebrafish larvae | Soak absorption | 0.1 μM | Changes in islet area, changes in fluorescence intensity caused by 2-NBDG | Effective dose: | [ | |
| Isoscutellarein 7-O-β- | Whole animal | Alloxan-induced islet damage model in | Soak absorption | 0.1 μM | Changes in islet area, changes in fluorescence intensity caused by 2-NBDG | Effective dose: | [ | |
| Whole animal | Alloxan-induced islet damage model in | Soak absorption | 1 μg/m | Changes in islet area, changes in fluorescence intensity caused by 2-NBDG | Effective dose: | [ | ||
| 3,5,6,9-tetrahydroxy-7-megastigmene | Whole animal | Alloxan-induced islet damage model in | Soak absorption | 1 μg/m | Changes in islet area, changes in fluorescence intensity caused by 2-NBDG | Effective dose: | [ | |
| n-hexane extract | Whole animal | Type 2 diabetes db/db mice | Oral administration | 10~40 mg/kg weight/d | Fasting blood glucose levels, non-fasting blood glucose levels, triglycerides, total cholesterol, high-density lipoprotein cholesterol, HTR (high-density lipoprotein cholesterol/total cholesterol), phosphorylation levels of AMPK and ACC in soleus muscle and liver | Effective dose: | [ | |
| β-sitosterol | Cellular level | L6 myotube cells | Incubation | 75~300 μM | Phosphorylation levels of AMPK and ACC, | Effective dose: | [ | |
| Neutral polysaccharide | Whole animal | Male mice | Intraperitoneal injection | 10~100 mg/kg | 0 h, 7 h and 24 h plasma glucose level | Effective dose: | [ | |
| Peptidoglycan MVS-V | Whole animal | Male mice | Intraperitoneal injection | 10~100 mg/kg | 0 h, 7 h and 24 h plasma glucose level | Effective dose: | [ | |
| Peptidoglycan-enriched fraction MVS-V-CH | Whole animal | Male mice | Intraperitoneal injection | 10~100 mg/kg | 0 h, 7 h and 24 h plasma glucose level | Effective dose: | [ | |
| Anti-oxidation | Nortangeretin-8-O-β- | Physical and chemical reaction | DPPH RS activity, | Incubation | 0.1 mL, | DPPH EC50, | DPPH EC50: >50 µM, | [ |
| Isoscutellarein 8-O-β- | Physical and chemical reaction | DPPH RS activity, | Incubation | DPPH EC50, | DPPH EC50: >50 µM, | [ | ||
| hypolaetin 8-O-β- | Physical and chemical reaction | DPPH RS activity, | Incubation | DPPH EC50, | DPPH EC50: 5.98 ± 0.24 µM, | [ | ||
| herbacetin 8-O-β- | Physical and chemical reaction | DPPH RS activity, | Incubation | DPPH EC50, | DPPH EC50: 31.79 ± 2.22 µM, | [ | ||
| herbacetin 3-O-β- | Physical and chemical reaction | DPPH RS activity, | Incubation | DPPH EC50, | DPPH EC50: 33.80 ± 1.89 µM, | [ | ||
| isoscutellarein | Physical and chemical reaction | DPPH RS activity, | Incubation | DPPH EC50, | DPPH EC50: >50 µM, | [ | ||
| 90% ethanol extract | Physical and chemical reaction | DPPH radical scavenging activity assay | Incubation | 100 μL (1–1000 μg/mL) | DPPH anion scavenging activity, | [ | ||
| Antitumor | Ethyl acetate extract | Cellular level | Splenocytes, | Incubation | 10 μg/mL | splenocyte proliferation ability, | Effective dose: | [ |
| Cellular level | HepG2, AGS, HCT-15, A549 | Incubation | 50% inhibitory concentration IC50 | IC50 ± SD: | [ | |||
| n-butanol extract | Cellular level | Splenocytes, | Incubation | 10 μg/mL | splenocyte proliferation ability, | Effective dose: | [ | |
| Cellular level | HepG2, AGS, HCT-15, A549 | Incubation | 10~40 μg/mL | 50% inhibitory concentration IC50, | IC50 ± SD: | [ | ||
| Water extract | Cellular level | Splenocytes, | Incubation | 10 μg/mL | splenocyte proliferation ability, | Effective dose: | [ | |
| Cellular level | HepG2, AGS, HCT-15, A549 | Incubation | 50% inhibitory concentration IC50 | IC50 ± SD: | [ | |||
| (2S)-1-O-palmitoyl glyceride | Cellular level | Splenocytes, | Incubation | 10 μM | splenocyte proliferation ability, | Effective dose: | [ | |
| (2S)-1-O-stearoyl glyceride | Cellular level | Splenocytes, | Incubation | 10 μM | splenocyte proliferation ability, | Effective dose: | [ | |
| (2S)-1-O-linolenoyl glyceride | Cellular level | Splenocytes, | Incubation | 10 μM | splenocyte proliferation ability, | Effective dose: | [ | |
| (2S)-1,2-di-O-linoleoyl glyceride | Cellular level | Splenocytes, | Incubation | 10 μM | splenocyte proliferation ability, | Effective dose: | [ | |
| (2S)-1-O-(6-deoxy-6-sulfo)-α-D | Cellular level | HepG2, AGS, HCT-15, A549 | Incubation | 25~100 μM | 50% inhibitory concentration IC50, | IC50 ± SD: | [ | |
| (2S)-1-O-(6-deoxy-6-sulfo)-α- | Cellular level | HepG2, AGS, HCT-15, A549 | Incubation | 20~80 μM | 50% inhibitory concentration IC50, | IC50 ± SD: | [ | |
| (2S)-1-O-β- | Cellular level | HepG2, AGS, HCT-15, A549 | Incubation | 50% inhibitory concentration IC50 | IC50 ± SD: | [ | ||
| (2S)-1-O-β- | Cellular level | HepG2, AGS, HCT-15, A549 | Incubation | 50% inhibitory concentration IC50 | IC50 ± SD: | [ | ||
| (2S)-1-O-β- | Cellular level | HepG2, AGS, HCT-15, A549 | Incubation | 50% inhibitory concentration IC50 | IC50 ± SD: | [ | ||
| (2S)-1-O-β- | Cellular level | HepG2, AGS, HCT-15, A549 | Incubation | 50% inhibitory concentration IC50 | IC50 ± SD: | [ | ||
| (2S)-1-O-β- | Cellular level | HepG2, AGS, HCT-15, A549 | Incubation | 50% inhibitory concentration IC50 | IC50 ± SD: | [ | ||
| (2S)-1-O-β- | Cellular level | HepG2, AGS, HCT-15, A549 | Incubation | 50% inhibitory concentration IC50 | IC50 ± SD: | [ | ||
| (2S)-1-O-6′-O-(α- | Cellular level | HepG2, AGS, HCT-15, A549 | Incubation | 50% inhibitory concentration IC50 | IC50 ± SD: | [ | ||
| (2S)-1-O-6′-O-(α- | Cellular level | HepG2, AGS, HCT-15, A549 | Incubation | 50% inhibitory concentration IC50 | IC50 ± SD: | [ | ||
| (2S)-1-O-6′-O-(α- | Cellular level | HepG2, AGS, HCT-15, A549 | Incubation | 10~40 μM | 50% inhibitory concentration IC50, | IC50 ± SD: | [ | |
| (2S)-1-O-(6-O-α- | Cellular level | HepG2, AGS, HCT-15, A549 | Incubation | 50% inhibitory concentration IC50 | IC50 ± SD: | [ | ||
| (2S)-1-O-(6-O-α- | Cellular level | HepG2, AGS, HCT-15, A549 | Incubation | 50% inhibitory concentration IC50 | IC50 ± SD: | [ | ||
| Hair-loss treatment | 95% ethanol extract | Cellular level | HFDPC cells | Incubation | 3~100 μg/mL | Cell proliferation rate | Effective dose: | [ |
| n-hexane extract | Cellular level | HFDPC cells | Incubation | 3~100 μg/mL | Cell proliferation rate | Effective dose: | [ | |
| Linoleic acid | Cellular level | HFDPC cells | Incubation | 3~30 μg/mL | Cell proliferation rate, Wnt/β-catenin signaling pathway proteins GSK-3β, β-catenin; Cyclin D1, CDK2, GAPDH; cell growth factor VEGF, IGF-1, HGF, KGF, GAPDH | Effective dose: | [ | |
| Ethanol extract | Cellular level | Human dermal papilla cells (DPCs) | Incubation | 0~50 μg/mL | Wnt reporter activity, expression of intracellular proteins β-catenin and GAPDH | Effective dose: | [ | |
| Dichloromethane extract | Cellular level | Human dermal papilla cells DPCs) | Incubation | 10~100 μg/mL | Wnt reporter activity, expression of intracellular proteins β-catenin and GAPDH | Effective dose: | [ | |
| Myristoleic acid | Cellular level | Human dermal papilla cells (DPCs) | Incubation | 0~100 μg/mL | Wnt reporter activity, cell number, expression of cytokines IGF-1, KGF, VEGF, HGF, GAPDH, | Effective dose: | [ |
Figure 10The typical chemical composition separated and identified from Fructus Malvae.
Figure 11The anti-diabetic effect of 2 flavonoids identified from Fructus Malvae.
Figure 12The anti-tumor effect of 2 glycosylglycerides identified from Fructus Malvae.